BET Bromodomain Inhibitor ZEN-3694

Phase 2Small molecule

BET Bromodomain Inhibitor ZEN-3694 is one of 182 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

181

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Prostate CancerActive, not recruiting

Endometrial CancerActive, not recruiting

Metastatic Colorectal AdenocarcinomaSuspended

Metastatic Colorectal CarcinomaRecruiting

Advanced Malignant Solid NeoplasmRecruiting

Recurrent Endometrial CarcinomaRecruiting

Triple-Negative Breast CancerPhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Endometrial CancerPhase 1

Active, not recruiting

Metastatic Colorectal AdenocarcinomaPhase 1

Suspended

Metastatic Colorectal CarcinomaPhase 1

Recruiting

Advanced Malignant Solid NeoplasmPhase 2

Recruiting

Recurrent Endometrial CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

BET Bromodomain Inhibitor ZEN-3694

NNational Cancer Institute (NCI)

Phase 2

2 2

DATROWAY

Daiichi Sankyo

Preclinical

4 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 5

Chantix

PPrism Pharmaceuticals

Preclinical

1 6

Avastin

Roche

Preclinical

4 7

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 10

Bisphosphonate

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Triple-Negative Breast Cancer

NCT05422794

Q2 2027

Phase 1Recruiting

Recurrent Endometrial Carcinoma

NCT05950464

Phase 1Recruiting

Metastatic Colorectal Carcinoma

NCT05803382

Q4 2027

Phase 2Recruiting

Advanced Malignant Solid Neoplasm

NCT05327010

Q2 2028

Phase 2Active, not recruiting

Prostate Cancer

NCT04471974

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Suspended·NNational Cancer Institute (NCI)·Phase 1·NCT05111561·42 enrolled

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05372640·45 enrolled

Safety and Efficacy1 trial

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT05019716·36 enrolled

Prostate Cancer1 trial

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting·RRahul Aggarwal·Phase 2·NCT04471974·61 enrolled

Triple-Negative Breast Cancer1 trial

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05422794·57 enrolled

Refractory Solid Tumors1 trial

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT05053971·49 enrolled

5 more indications

Solid Tumors1 trial

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Suspended·NNational Cancer Institute (NCI)·Phase 1·NCT04840589·66 enrolled

Advanced Malignant Solid Neoplasm1 trial

Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05327010·88 enrolled

Recurrent Endometrial Carcinoma1 trial

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05950464·65 enrolled

Metastatic Colorectal Carcinoma1 trial

Phase I Trial of ZEN003694 (ZEN-3694) in Combination With Capecitabine in Patients With Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05803382·30 enrolled

Metastatic Colorectal Adenocarcinoma1 trial

A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer

Suspended·NNational Cancer Institute (NCI)·Phase 1·NCT06102902·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for BET Bromodomain Inhibitor ZEN-3694. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BET Bromodomain Inhibitor ZEN-3694 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BET Bromodomain Inhibitor ZEN-3694. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

BET Bromodomain Inhibitor ZEN-3694

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Breast Cancer2 trials

Safety and Efficacy1 trial

Prostate Cancer1 trial

Triple-Negative Breast Cancer1 trial

Refractory Solid Tumors1 trial

Solid Tumors1 trial

Advanced Malignant Solid Neoplasm1 trial

Recurrent Endometrial Carcinoma1 trial

Metastatic Colorectal Carcinoma1 trial

Metastatic Colorectal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News